Health news
Fatigue was not improved among patients with inflammatory bowel disease (IBD) after daily thiamine treatment. These findings, from a randomized, open-label, controlled long-term extension (LTE) trial, were published in the Scandinavian Journal of Gastroenterology. This…
The Food and Drug Administration (FDA) has approved Yusimry (adalimumab-aqvh), a biosimilar to Humira® (adalimumab). Yusimry, a tumor necrosis factor (TNF) blocker, is indicated for: Rheumatoid arthritis (RA): reducing signs/symptoms, inducing major clinical response, inhibiting…
The rate of antidrug antibody formation to biologics used in the treatment of inflammatory bowel disease (IBD) was assessed in a systematic review and meta-analysis published in BioDrugs. Given that immunogenicity to biologics may contribute…
The Food and Drug Administration (FDA) has cleared the PillCam Small Bowel 3 @HOME program, which allows patients to undergo endoscopy procedures under remote supervision in their homes. Using Medtronic’s PillCam technology with Amazon logistics,…
The Food and Drug Administration has approved Cyltezo® (adalimumab-adbm) as the first interchangeable biosimilar to Humira® (adalimumab). Cyltezo, a tumor necrosis factor (TNF) blocker, is indicated to treat adults with rheumatoid arthritis, psoriatic arthritis, ankylosing…
AbbVie has submitted a regulatory application to the Food and Drug Administration for risankizumab-rzaa for the treatment of patients 16 years of age and older with moderate to severe Crohn disease. The application is supported…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021